Abstract
To Editor. — As family practitioners working in community health centers, we were dismayed to receive a letter (March 1, 1990) informing us of National Association of Community Health Centers' involvement with Suprax Family Health Fund. Lederle Laboratories has donated $10 million worth of cefixime to be distributed free of charge to patients at community health clinics. Cefixime, a third-generation cephalosporin, is marketed by Lederle for the treatment of otitis media, pharyngitis, tonsillitis, acute bronchitis, acute exacerbations of chronic bronchitis, and uncomplicated urinary tract infections. The Medical Letter on Drugs and Therapeutics reviewed clinical trials comparing cefixime with amoxicillin and cefaclor in treatment of urinary tract infection, otitis media, pharyngitis, and bronchitis and concludes that cefixime... demonstrated no clinical advantage over previously available drugs including some that cost much less. 2 We are concerned that using a third-generation cephalosporin to treat uncomplicated infections may select for
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
